Pfizer (PFE) Secures $1.5 Billion For Berobenatide Development
Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?
Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market
Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug
Blackstone bets $1.5B on Pfizer’s obesity drug
Pfizer Says Will Discontinue Premarin Vaginal Cream And Three Tablet Strengths In Canada; Says Decision Made Following Internal Review, Not Related To Safety, Efficacy Or Quality Concerns
Blackstone Bankrolls Pfizer’s Weight Loss Drug Trials for Slice of Future Sales
Pfizer (PFE) Posts Phase 3 ELREXFIO Win And Expands AI Research Push
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer (PFE) On A Higher 2026 Outlook Still Looks About Right
Pfizer (PFE) Stock Looks Overvalued On Its 29% One Year Gain
Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
What Happens To Pfizer Stock If Patent Losses Outpace New Drugs?
Pfizer (PFE) Maps Out $650 Million Connecticut Center For Global Clinical Trials
Pfizer (PFE) Stock Looks Attractive for Income Investors
Guggenheim Maintains Buy on Pfizer, Raises Price Target to $33
Pfizer: The Portfolio Transformation Is Gaining Momentum
Pfizer (PFE) Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
Missed Out On Pfizer's Run? Here Is What Holders Saw
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.